High-throughput plasma proteomics reveals circulating biomarkers of interstitial lung disease and progressive pulmonary fibrosis in systemic sclerosis
Annals of the Rheumatic Diseases · 2026-11 · 85 (11) · 2208-2218
DOI: 10.1016/j.ard.2026.06.037 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-11. Verfasst von Elias Gerges und 22 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Centre National de la Recherche Scientifique…. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Proteomics, Scleroderma, Systemic, Pulmonary Fibrosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association des Sclérodermiques de France, World Scleroderma Foundation.
Abstract (Originalsprache)
OBJECTIVES: This study aimed to identify plasma biomarkers associated with systemic sclerosis-related interstitial lung disease (SSc-ILD) and progressive pulmonary fibrosis (SSc-PPF) using an unbiased proteomic approach, and to assess their predictive value across independent cohorts. METHODS: Plasma from 202 patients with SSc was analysed, including a discovery cohort (n = 45) and a replication cohort (n = 157) from 3 centres (Paris, Bordeaux, Leeds). Patients were stratified by ILD status (SSc without ILD [SSc-NoILD] vs SSc-ILD) and ILD progression (SSc with nonprogressive pulmonary fibrosis [SSc-NoPPF] vs SSc-PPF), with SSc-PPF defined according to INBUILD criteria. Mass spectrometry-based proteomics identified candidate biomarkers in the discovery cohort. Top candidates were evaluated by enzyme-linked immunosorbent assay (ELISA) in the replication cohort. Differential expression, pathway enrichment, and predictive performance analyses were performed. RESULTS: A total of 1507 proteins were quantified, of which 44 and 51 were associated with SSc-ILD and SSc-PPF, respectively. Five candidates progressed to ELISA validation, among which surfactant protein D (SP-D) and matrix metalloproteinase 8 (MMP-8) were successfully replicated. In the combined cohort, SP-D was elevated in SSc-ILD vs SSc-NoILD (17.36 ± 11.99 vs 9.49 ± 7.92 ng/mL; P < .0001). MMP-8 was higher in SSc-PPF vs SSc-NoPPF (17.67 ± 12.45 vs 10.77 ± 10.92 ng/mL; P < .001). Its prognostic value for PPF was further replicated in another cohort of 113 patients from Tokyo and Milan. In combined analyses, MMP-8 independently predicted SSc-PPF and improved performance when added to clinical variables. CONCLUSIONS: SP-D and MMP-8 emerge as candidate biomarkers for diagnosing SSc-ILD and predicting SSc-PPF, respectively. Their validation across multicentric cohorts supports their relevance for clinical risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Centre National de la Recherche Scientifique Unité mixte de recherche 8104, Paris, France.
- Université Paris Cité, Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Centre National de la Recherche Scientifique Unité mixte de recherche 8104, Paris, France; Rheumatology Department…
- Biochemistry Department, Hôpital Cochin, Assistance Publique Hopitaux de Paris, Université Paris Cité, Paris, France.
- Proteom'IC facility, Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France.
- Rheumatology Department, University Hospital of Bordeaux, Centre de Référence des Maladies Auto-immunes Systémiques Rares Du Sud-Ouest, Bordeaux, France.
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, Rheumatology Department, University of Leeds, Leeds, UK; National Institute for Health and Care Research Leeds Biomedical Research Centre, Leeds Teaching Hospit…
Förderung
- Association des Sclérodermiques de France
- World Scleroderma Foundation
Zitieren
APA
Gerges, E., Cauvet, A., Guedot, M., Dahan, M., Mairet, M., Avouac, J., Gobeaux, C., Gautier, E. F., Gall, M. L., Clary, G., Bébéar, L., Truchetet, M. E., Mulipa, P., Monterosso, C., Ross, R. L., Kuwana, M., Shirai, Y., Molteni, R., Campochiaro, C., …, & Allanore, Y. (2026). High-throughput plasma proteomics reveals circulating biomarkers of interstitial lung disease and progressive pulmonary fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 85(11), 2208-2218. https://doi.org/10.1016/j.ard.2026.06.037
Vancouver
Gerges E, Cauvet A, Guedot M, Dahan M, Mairet M, Avouac J, et al. High-throughput plasma proteomics reveals circulating biomarkers of interstitial lung disease and progressive pulmonary fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases. 2026;85(11):2208-2218. doi:10.1016/j.ard.2026.06.037
BibTeX
@article{Gerges2026,
author = {Gerges, Elias and Cauvet, Anne and Guedot, Margot and Dahan, Mélodie and Mairet, Mathieu and Avouac, Jérôme and Gobeaux, Camille and Gautier, Emilie-Fleur and Gall, Morgane Le and Clary, Guilhem and Bébéar, Louis and Truchetet, Marie-Elise and Mulipa, Panji and Monterosso, Costanza and Ross, Rebecca L and Kuwana, Masataka and Shirai, Yuichiro and Molteni, Raffaella and Campochiaro, Corrado and Matucci-Cerinic, Marco and Iannone, Claudia and Galdo, Francesco Del and Allanore, Yannick},
title = {High-throughput plasma proteomics reveals circulating biomarkers of interstitial lung disease and progressive pulmonary fibrosis in systemic sclerosis},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {11},
pages = {2208--2218},
doi = {10.1016/j.ard.2026.06.037}
}
EUVIMED